Trials / Terminated
TerminatedNCT03669640
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO6889450 | Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks. |
| DRUG | Placebo | Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks. |
Timeline
- Start date
- 2018-12-04
- Primary completion
- 2023-03-12
- Completion
- 2023-03-12
- First posted
- 2018-09-13
- Last updated
- 2024-08-12
- Results posted
- 2024-08-12
Locations
45 sites across 4 countries: United States, Japan, Spain, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03669640. Inclusion in this directory is not an endorsement.